Day One Biopharmaceuticals Inc (DAWN)
13.27
-0.33
(-2.43%)
USD |
NASDAQ |
May 31, 16:00
13.27
0.00 (0.00%)
After-Hours: 20:00
Day One Biopharmaceuticals Enterprise Value: 841.72M for May 31, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 31, 2024 | 841.72M |
| May 30, 2024 | 870.56M |
| May 29, 2024 | 884.54M |
| May 28, 2024 | 871.43M |
| May 24, 2024 | 885.41M |
| May 23, 2024 | 894.15M |
| May 22, 2024 | 959.70M |
| May 21, 2024 | 974.55M |
| May 20, 2024 | 1.078B |
| May 17, 2024 | 1.095B |
| May 16, 2024 | 1.083B |
| May 15, 2024 | 1.117B |
| May 14, 2024 | 1.134B |
| May 13, 2024 | 1.085B |
| May 10, 2024 | 1.080B |
| May 09, 2024 | 1.114B |
| May 08, 2024 | 1.116B |
| May 07, 2024 | 1.175B |
| May 06, 2024 | 1.133B |
| May 03, 2024 | 1.183B |
| May 02, 2024 | 1.217B |
| May 01, 2024 | 1.228B |
| April 30, 2024 | 1.176B |
| April 29, 2024 | 1.122B |
| April 26, 2024 | 985.72M |
| Date | Value |
|---|---|
| April 25, 2024 | 836.31M |
| April 24, 2024 | 1.009B |
| April 23, 2024 | 1.136B |
| April 22, 2024 | 1.026B |
| April 19, 2024 | 989.22M |
| April 18, 2024 | 1.058B |
| April 17, 2024 | 979.61M |
| April 16, 2024 | 958.64M |
| April 15, 2024 | 892.23M |
| April 12, 2024 | 885.24M |
| April 11, 2024 | 910.58M |
| April 10, 2024 | 941.16M |
| April 09, 2024 | 938.54M |
| April 08, 2024 | 901.84M |
| April 05, 2024 | 955.14M |
| April 04, 2024 | 922.81M |
| April 03, 2024 | 1.045B |
| April 02, 2024 | 1.066B |
| April 01, 2024 | 1.094B |
| March 28, 2024 | 1.077B |
| March 27, 2024 | 1.013B |
| March 26, 2024 | 989.75M |
| March 25, 2024 | 946.06M |
| March 22, 2024 | 992.37M |
| March 21, 2024 | 949.55M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
91.41M
Minimum
May 27 2022
1.557B
Maximum
Aug 12 2022
878.22M
Average
909.44M
Median
Enterprise Value Benchmarks
| Revolution Medicines Inc | 4.620B |
| Iovance Biotherapeutics Inc | 2.130B |
| Beam Therapeutics Inc | 866.10M |
| Zentalis Pharmaceuticals Inc | 354.65M |
| Perspective Therapeutics Inc | 680.29M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -62.41M |
| Total Expenses (Quarterly) | 66.77M |
| EPS Diluted (Quarterly) | -0.72 |
| Earnings Yield | -18.91% |
| Operating Earnings Yield | 23.16% |
| Normalized Earnings Yield | 15.96 |